ELYM ELIEM THERAPEUTICS INC

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.

Stifel 2024 Virtual Immunology and Inflammation Summit

Date: Wednesday, September 18, 2024

Format: 1x1 meetings

About Eliem Therapeutics, Inc.

Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit .

Investors

Chris Brinzey

ICR Westwicke



339-970-2843



EN
11/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results ...

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates  Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage ...

Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip

ResearchPool Subscriptions

Get the most out of your insights

Get in touch